Double specific cancer immunotherapy! Mosunetuzumab and cd20-tcb showed strong efficacy in the treatment of refractory lymphoma!

December 10, 2019 / BIOON / -- the 61st annual meeting of the American Society of Hematology (ash2019) was recently held in Orlando, Florida, USA At the meeting, Roche released new data on two types of research cd20-cd3 T cells combined with bispecific antibodies (mosunetuzumab and cd20-tcb) for the treatment of relapsed or refractory B-cell non-Hodgkin's lymphoma (R / R B-NHL) The go29781 study (nct02500407) is a multicenter, open label, incremental dose I / IB phase study that is evaluating the safety and pharmacokinetics of mosunetuzumab in R / R B-NHL patients Patients included in the study included patients who relapsed after receiving car-t cell therapy or who were resistant to car-t cell therapy, with limited treatment options The aim of the study was to assess the optimal objective response rate (ORR) using revised International Working Group criteria, maximum tolerable dose and tolerability The results showed that mosunetuzumab showed encouraging effects: (1) in orr, 62.7% (n = 42 / 67) of patients with inert NHL and 37.1% (n = 46 / 124) of patients with invasive NHL (2) In terms of complete remission rate (CR), 43.3% (n = 29 / 67) in patients with inert NHL and 19.4% (n = 24 / 124) in patients with invasive NHL (3) CR showed persistence 82.8% (n = 24 / 29) of patients with inert NHL were still in remission state 26 months after initial treatment, and 70.8% (n = 17 / 24) of patients with invasive NHL were still in remission state 16 months after initial treatment (4) In patients who had previously received car-t cell therapy, Orr was 38.9% (n = 7 / 18) and Cr was 22.2% (n = 4 / 18) (5) In terms of adverse reactions, 28.9% of the patients had cytokine release syndrome (CRS), 20.0% of them were grade 1, 1.1% were grade 3, and grade 3 neurological adverse events occurred in 3.7% of the patients Np30179 study (nct03075696) is a multicenter, open label, dose increasing I / IB phase It is evaluating the efficacy, safety, tolerance and pharmacokinetics of cd20-tcb in the treatment of R / rb-nhl patients In this study, patients were treated with cd20-tcb (group A), cd20-tcb (dose range 0.6-16mg) and gazyva / gazyvaro (group B) after a one-time, fixed dose of gazyva / gazyvaro (a CD20 mAb) pretreatment The aim of the study was to assess the optimal objective response rate (ORR, using Lugano 2014 criteria), maximum tolerable dose and tolerability The results from group B were published for the first time The data showed that: (1) the orr of CD20 TCB + gazyva / gazyvaro combined therapy was 54% (n = 15 / 28), and the CR was 46% (n = 13 / 28) (2) In patients with follicular lymphoma (FL), Orr and Cr were 66.7% (n = 4 / 6); in patients with invasive NHL, Orr was 50.0% (n = 11 / 22) and Cr was 40.9% (n = 9 / 22) (3) The most common adverse event observed in all treatment doses was cytokine release syndrome (CRS), which occurred in 67.9% (n = 19 / 28), and most of the events were of low level (1-2) Both mosunetuzumab and CD20 TCB are cd20-cd3 T cell binding bispecific antibodies, targeting CD20 on the surface of B cells and CD3 on the surface of T cells This dual targeting can activate and reorient the patient's existing T cells and eliminate the target B cells by releasing toxic proteins into the B cells The structure of mosunetuzumab is similar to that of human natural antibody, but it contains two Fab regions, one of which is targeted at CD20 and the other is targeted at CD3 Cd20-tcb has a novel structure pattern of "2:1", including two Fab regions targeting CD20 and one Fab region targeting CD3 These two antibodies are part of Roche's strategy to explore several bispecific antibody patterns to identify options that maximize potential clinical benefits for patients At present, Roche is developing mosunetuzumab and cd20-tcb as a single drug therapy and in combination with other drugs to treat CD20 positive B-cell non-Hodgkin's lymphoma, including diffuse large B-cell lymphoma and follicular lymphoma Levi Garraway, MD, Roche's chief medical officer and head of global product development, said: "although treatment progress has been made in recent years, with each recurrence, inert and aggressive NHL are facing increasingly difficult treatment challenges We are encouraged by these early results, which suggest that our new dual specific cancer immunotherapy may help patients with recurrent or refractory diseases who need more options " Source: Roche announcements new data on new cd20-cd3 biological cancer immunity in people with efficient to treat lymphamas